4.4 Article

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Journal

JOURNAL OF CLINICAL LIPIDOLOGY
Volume 5, Issue 3, Pages 133-140

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2011.03.001

Keywords

Familial hypercholesterolemia; LDL receptor; Apheresis; Cascade screening; Heterozygous; Heterozygote; Homozygous; Homozygote

Funding

  1. Abbott Laboratories
  2. Aegerion Pharmaceuticals
  3. Daiichi Sankyo
  4. Genzyme
  5. Kaneka Pharma America LLC
  6. Merck Co.
  7. American Diabetes Association
  8. American Heart Association
  9. AstraZeneca
  10. Bristol-Myers Squibb
  11. diaDexus
  12. GlaxoSmithKline
  13. Kowa Pharmaceuticals
  14. National Institutes of Health
  15. Novartis
  16. Roche/Genentech
  17. Sanofi-Synthelabo
  18. Takeda Pharmaceuticals
  19. Isis Pharmaceuticals
  20. Amarin
  21. ISIS-Genzyme Corporation
  22. Regeneron
  23. Hoffman LaRoche
  24. Merck Schering Plough
  25. Spirocor
  26. Genzyme Corporation

Ask authors/readers for more resources

The familial hypercholesterolemias (FH) are a group of genetic defects resulting in severe elevations of blood cholesterol levels and increased risk of premature coronary heart disease. FH is among the most commonly occurring congenital metabolic disorders. FH is a treatable disease. Aggressive lipid lowering is necessary to achieve the target LDL cholesterol reduction of at least 50% or more. Even greater target LDL cholesterol reductions may be necessary for FH patients who have other CHD risk factors. Despite the prevalence of this disease and the availability of effective treatment options, FH is both underdiagnosed and undertreated, particularly among children. Deficiencies in the diagnosis and treatment of FH indicate the need for greatly increased awareness and understanding of this disease, both on the part of the public and of healthcare practitioners. This document provides recommendations for the screening, diagnosis and treatment of FH in pediatric and adult patients developed by the National Lipid Association Expert Panel on Familial Hypercholesterolemia. This report goes beyond previously published guidelines by providing specific clinical guidance for the primary care clinician and lipid specialist with the goal of improving care of patients with FH and reducing their elevated risk for CHID. (C) 2011 National Lipid Association. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available